Neurofibromatosis Pipeline Analysis report covers 15 drugs currently in different phases of development. Neurofibromatosis is a genetic disorder characterised by formation of tumors on nerve tissue. There are 3 main types of neurofibromatosis: Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2) and Schwannomatosis. Neurofibromatosis type 1 (NF1) is the most common type of neurofibromatosis followed by NF2 and Schwannomatosis. Symptoms of the disease includes presence of café-au-lait spots, Lisch nodules, optic glioma, skeletal defects and freckling under the arms or in groin.
The report provides Neurofibromatosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Betta Pharmaceuticals Co.,Ltd., E.Z. BioXcel, Lixte Biotechnology Holdings, Inc. and Recursion Pharmaceuticals, Inc. among others.
Scope:
By Company
By Phase
NDA filed
Phase III
Phase II
Phase I
Pre-clinical
Discovery
By Molecule Type
Small molecules
Biologics
Peptides or Small proteins
By Region
North America
South America
Europe
Middle East and Africa
Asia Pacific
By Route of Administration
IV
IM
S/C
Oral
Intratumoral